Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Jul

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers

Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs

Long-Term Outcomes With SABR in Primary Kidney Cancer